This Site All Sites

     Broad Patient Populations
 

ACEON® 8 mg—Provides Benefits in Patients Receiving Contemporary CV Protective Therapies 1,2
 

 
ACEON® reduces the risk of CV mortality or nonfatal MI across a broad range of stable CAD patients 1,2:

Regardless of
  • Gender
  • Age
  • Hypertension
  • Previous MI
  • Diabetes
  • Revascularization
 ...and including those on the following concomitant therapies
  • Antiplatelet therapies (92%)
  • Beta-blockers (63%)
  • Lipid-lowering agents (56%)
  • Calcium channel blockers (32%)

USE IN PREGNANCY 2
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, ACEON® should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.